Back to Browse Journals » Biologics: Targets and Therapy » Volume 5

Gut microbiota: next frontier in understanding human health and development of biotherapeutics

Authors Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C

Published Date July 2011 Volume 2011:5 Pages 71—86

DOI http://dx.doi.org/10.2147/BTT.S19099

Published 11 July 2011

Satya Prakash, Laetitia Rodes, Michael Coussa-Charley, Catherine Tomaro-Duchesneau
Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering and Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, Montreal, Quebec, Canada

Abstract: The gut microbiota is a remarkable asset for human health. As a key element in the development and prevention of specific diseases, its study has yielded a new field of promising biotherapeutics. This review provides comprehensive and updated knowledge of the human gut microbiota, its implications in health and disease, and the potentials and limitations of its modification by currently available biotherapeutics to treat, prevent and/or restore human health, and future directions. Homeostasis of the gut microbiota maintains various functions which are vital to the maintenance of human health. Disruption of the intestinal ecosystem equilibrium (gut dysbiosis) is associated with a plethora of human diseases, including autoimmune and allergic diseases, colorectal cancer, metabolic diseases, and bacterial infections. Relevant underlying mechanisms by which specific intestinal bacteria populations might trigger the development of disease in susceptible hosts are being explored across the globe. Beneficial modulation of the gut microbiota using biotherapeutics, such as prebiotics, probiotics, and antibiotics, may favor health-promoting populations of bacteria and can be exploited in development of biotherapeutics. Other technologies, such as development of human gut models, bacterial screening, and delivery formulations eg, microencapsulated probiotics, may contribute significantly in the near future. Therefore, the human gut microbiota is a legitimate therapeutic target to treat and/or prevent various diseases. Development of a clear understanding of the technologies needed to exploit the gut microbiota is urgently required.

Keywords: gut microbiota, human health, dysbiosis, biotherapeutics, probiotics, microencapsulation

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA

Malhotra M, Tomaro-Duchesneau C, Saha S, Kahouli I, Prakash S

International Journal of Nanomedicine 2013, 8:2041-2052

Published Date: 21 May 2013

A novel polyethyleneimine-coated adeno-associated virus-like particle formulation for efficient siRNA delivery in breast cancer therapy: preparation and in vitro analysis

Shao W, Paul A, Abbasi S, Chahal PS, Mena JA, Montes J, Kamen A, Prakash S

International Journal of Nanomedicine 2012, 7:1575-1586

Published Date: 23 March 2012

Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction

Paul A, Nayan M, Khan AA, Shum-Tim D, Prakash S

International Journal of Nanomedicine 2012, 7:663-682

Published Date: 8 February 2012

Diet-induced metabolic hamster model of nonalcoholic fatty liver disease

Bhathena J, Kulamarva A, Martoni C, Urbanska A, Malhotra M,  Paul A, Prakash S

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011, 4:195-203

Published Date: 3 June 2011

Mitotic and antiapoptotic effects of nanoparticles coencapsulating human VEGF and human angiopoietin-1 on vascular endothelial cells

Khan AA, Paul A, Abbasi S, Prakash S

International Journal of Nanomedicine 2011, 6:1069-1081

Published Date: 24 May 2011

A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis

Meenakshi Malhotra, Ciaran Lane, Catherine Tomaro-Duchesneau, et al

International Journal of Nanomedicine 2011, 6:485-494

Published Date: 3 March 2011

Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis

Safaa Sebak, Maryam Mirzaei, Meenakshi Malhotra, et al

International Journal of Nanomedicine 2010, 5:525-532

Published Date: 15 September 2010

Potentials and limitations of microorganisms as renal failure biotherapeutics

Poonam Jain, Sapna Shah, Razek Coussa, Satya Prakash

Biologics: Targets and Therapy 2009, 3:233-243

Published Date: 18 May 2009

Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells

Arvind Kumar, Tryambak D Singh, Santosh K Singh, Satya Prakash

Biologics: Targets and Therapy 2009, 3:245-256

Published Date: 15 May 2009

Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells

Satya Prakash, Aleksandra Malgorzata Urbanska

Biologics: Targets and Therapy 2008, 2:355-378

Published Date: 29 September 2008

Readers of this article also read:

IBS-like symptoms in patients with ulcerative colitis

Gracie DJ, Ford AC

Clinical and Experimental Gastroenterology 2015, 8:101-109

Published Date: 19 February 2015

Vaginal Lactobacillus: biofilm formation in vivo – clinical implications

Ventolini G

International Journal of Women's Health 2015, 7:243-247

Published Date: 16 February 2015

"It is the left eye, right?"

Pikkel D, Sharabi-Nov A, Pikkel J

Risk Management and Healthcare Policy 2014, 7:77-80

Published Date: 8 April 2014

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Vitamin D deficiency: A potential risk factor for Clostridium difficile infection

Youssef D, Grant WB, Peiris AN

Risk Management and Healthcare Policy 2012, 5:115-116

Published Date: 8 October 2012

Current and emerging drugs for the treatment of inflammatory bowel disease

Triantafillidis JK, Merikas E, Georgopoulos F

Drug Design, Development and Therapy 2011, 5:185-210

Published Date: 6 April 2011